Abstract:Phosphoinositide 3-kinase (PI3K) is a key regulator of cell proliferation, survival, and metabolism. Hotspot mutations in the PIK3CA gene constitutively activate the catalytic subunit of the PI3Kα isoform and are found in 10-30% of solid tumors. The development of PI3K pathway inhibitors has been hampered by poor drug tolerance and release of negative feedback loops, leading to rapid reactivation of signaling in response to reversible inhibitors. To remedy these challenges, we developed highly selective covalent PI3Kα inhibitors that irreversibly bind to a non-conserved cysteine (C862) located 11 Å outside the ATP-binding site. Here we present the properties of an optimized drug-like covalent lead, dubbed compound 9, and describe the generation of a biotinylated probe developed to be used in conjunction with compound 9 to monitor PI3Kα target occupancy in relation to downstream PI3K signaling outputs. Biochemical investigations of compound 9 using TR-FRET assays showed high affinity binding (Ki), high reaction rates (kinact) for covalent bond formation with PI3Kα, and negligible off-target reactivity. Cellular NanoBRET assays revealed that compound 9 diffuses three times more rapidly into cells as compared to BYL719 (alpelisib), and leads to rapid and potent on-target engagement. Covalent bond formation to residue C862 of PI3Kα was further confirmed by X-ray crystallography. In PIK3CA mutant cancer cell lines, covalent binding of PI3Kα occurred at low nanomolar concentrations and led to persistent inhibition of Akt/PKB phosphorylation for more than 72 hours after drug removal. Notably, investigation of PI3Kα re-synthesis after labeling with compound 9 showed a negligible reappearance in cancer cell lines, which indicates that persistent suppression of PI3Kα signaling by compound 9 results in a much longer half-life for PI3Kα than previously reported. The irreversible inactivation of PI3Kα by compound 9 provides a marked gain in growth inhibition potency (10-600-fold) in PIK3CA mutant cancer cell lines in comparison to clinical reversible PI3Kα inhibitors and allows for intermittent dosing without compromising efficacy. These data collectively demonstrate that compound 9 enables precise and selective targeting of PI3Kα with high potency and long-lasting efficacy in cancer models. The new class of irreversible PI3Kα inhibitors have a unique pharmacology among PI3K inhibitors characterized by strong decoupling of drug exposure from efficacy which may provide opportunities to lower treatment burden in patients. Citation Format: Theodora A. Constantin, Lukas Bissegger, Erhan Keleş, Luka Raguž, Clara Orbegozo, Thorsten Schaefer, Isobel Barlow-Busch, John E. Burke, Chiara Borsari, Matthias P. Wymann. Novel long-acting covalent PI3Kα inhibitors boost potential action in cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1955.

ATP-competitive inhibitors of PI3K enzymes demonstrate an isoform selective dual action by controlling membrane binding

Development of small-molecule inhibitors that target PI3K13

Development of small-molecule inhibitors that target PI3Kβ

PI3K Inhibitors for Cancer Therapy: What Has Been Achieved So Far?

Exploring the Selective Mechanism of Inhibitors Towards Different Subtypes of Class I PI3K

Small Molecules Targeting Phosphoinositide 3-Kinases

Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.

Novel inhibitors of the PI3K family

Understanding the Selectivity of Inhibitors Toward PI4KIIIα and PI4KIIIβ Based Molecular Modeling

Abstract 1954: Development of highly potent, covalent, and selective inhibitors to target PI3Kα in cancer

The mechanism of PI3Kα activation at the atomic level

Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein

Advances in Subunits of PI3K Class I in Cancer.

Precision Targeting of Mutant PI3Kα

Targeting Phosphatidylinositol 3‐kinase Gamma (pi3kγ): Discovery and Development of Its Selective Inhibitors

Theoretical Studies on Beta and Delta Isoform-Specific Binding Mechanisms of Phosphoinositide 3-Kinase Inhibitors.

Synthesis and Sar of Novel 4-Morpholinopyrrolopyrimidine Derivatives As Potent Phosphatidylinositol 3-Kinase Inhibitors

Abstract 1955: Novel long-acting covalent PI3Kα inhibitors boost potential action in cancer

Cryo-EM structures of PI3K reveal conformational changes during inhibition and activation

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Development of PI3Kγ selective inhibitors: the strategies and application